Incretin Atlas › Trials › REDEFINE 5 (vs semaglutide 2.4 mg)
REDEFINE 5 (vs semaglutide 2.4 mg)
CagriSema · obesity
Design
- Molecule(s)
- CagriSema
- Population
- obesity
- Official title
- A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight
- Sponsor
- Novo Nordisk A/S
- Phase
- 3
- Registry status
- completed · 2023-04 → 2025-01
- Participants
- 331
- Duration
- 68 weeks
- Registry
- NCT05813925
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CagriSema 2.4/2.4 mg vs semaglutide 2.4 mg: −11.9 % (efficacy) | obesity | 68 | 164 | −18.4 % | −16.9 % | −1.1 | 2.0 | 10.0 | — | — | 4.0 | −10.0 | verified |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Verbatim quotes from the source (7)
- CagriSema 2.4/2.4 mg · weight_eff · Table 2
Change in bodyweight† −18·4% −11·9% −6·5 (−8·4 to −4·6) <0·0001
- CagriSema 2.4/2.4 mg · weight_tp · Results, paragraph 4 (treatment policy estimand)
had a mean change in bodyweight of –16·9% (0·7) versus –11·1% (0·7) for semaglutide
- CagriSema 2.4/2.4 mg · ae_dc · Results, paragraph 10; Table 3
cagrilintide–semaglutide group (three [2%] participants) and the semaglutide group (four [2%]; table 3)
- CagriSema 2.4/2.4 mg · disc_any · Summary, Findings; Results paragraph 1
17 (10%) participants discontinued cagrilintide–semaglutide and ten (6%) discontinued semaglutide.
- CagriSema 2.4/2.4 mg · sae · Results, paragraph 10; Table 3
Serious adverse events were reported in six (4%) participants receiving cagrilintide–semaglutide and 11 (7%) receiving semaglutide
- CagriSema 2.4/2.4 mg · hba1c · Table 2
Change in HbA1c, %§ −1·1 −1·0 −0·1 (−0·2 to 0·0) 0·017
- CagriSema 2.4/2.4 mg · sbp · Table 2
Change in systolic blood pressure, mmHg§ −10·0 −5·2 −4·9 (−7·7 to −2·0) 0·0008
Primary sources
- Yamauchi T, Becker NP, Hagemann CA, Huang KC, Kiyosue A, Lim S, et al. Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial. Lancet Diabetes Endocrinol. 2026;14(6):450-462. PMID: 42009015.
- ClinicalTrials.gov NCT05813925
How to cite this page
Medical Adviser's Group. Incretin Atlas: REDEFINE 5 (vs semaglutide 2.4 mg). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/redefine-5/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.